United Orthopedic Gains Clearance for E-XPE Hip Liner
United Orthopedic received FDA 510(k) clearance to market the E-XPE vitamin E highly cross-linked polyethylene-based hip liner....
Nov 27, 2018,
Joint Replacement
ORTHOFLASHFirst Procedures with Integra’s XT Revision Total Ankle
Integra LifeSciences launched the Integra® XT Revision Total Ankle Replacement system....
Nov 26, 2018, Julie Vetalice
Smith & Nephew: Positive Study Results for JOURNEY II BACS Knee
New clinical evidence represents positive mid-term survivorship results on 2,059 patients with Smith & Nephew's JOURNEY II BCS knee....
Nov 19, 2018, Julie Vetalice
FDA Approves IDE Study of BioPoly RS Partial Resurfacing Knee
BioPoly received FDA approval to conduct an IDE clinical study of the BioPoly® RS Partial Resurfacing Knee....
Nov 16, 2018, Julie Vetalice
Shoulder Innovations Gains FDA Clearance for InSet Humeral Short Stem
Shoulder Innovations received FDA 510(k) clearance to market the InSet Humeral Short Stem....
Nov 05, 2018, Julie Vetalice
Medacta Gains FDA Clearance for Kinematic Knee Alignment
Medacta received FDA 510(k) clearance to market the GMK® Sphere “ Kinematic Alignment surgical technique and technique-specific instruments for total knee arthroplasty....
Nov 02, 2018, Julie Vetalice
DJO Launches Outpatient Risk Assessment Tool
DJO launched OaraScore Outpatient Arthroplasty Risk Assessment tool....
Nov 01, 2018, Julie Vetalice
DJO Introduces Additions to EMPOWR Knee Platform
DJO commenced launch of two additions to the EMPOWR Knee Platform”the EMPOWR Porous Knee and EMPOWR Complex Primary Knee....
Nov 01, 2018, Julie Vetalice
OsteoRemedies Launches Dual-Antibiotic Spacer and Bone Cement
OsteoRemedies launched the REMEDY SPECTRUM™️ GV Hip Spacer and SPECTRUM™️ GV Bone Cement....
Nov 01, 2018, Julie Vetalice
Zimmer Biomet Gains FDA 510(k) Clearance for PERSONA Revision Knee
Zimmer Biomet received FDA 510(k) clearance to market the PERSONA® revision knee, featuring patient-specific components....
Oct 31, 2018, Julie Vetalice
Loading new posts...
No more posts
